Nutriband Inc. (NASDAQ: NTRB), a company focused on transdermal pharmaceutical products, has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office aimed at bolstering intellectual property protection for its AVERSA™ abuse-deterrent transdermal technology. The application covers improved aversive formulations and coating methods designed to enhance the technology's abuse-deterrent properties. If granted, the patent could extend protection for AVERSA™-based products, including AVERSA™ FENTANYL, through 2046. This move is significant because it could provide Nutriband with a longer exclusivity period for its lead product candidate, potentially increasing its commercial value and competitive advantage in the opioid abuse-deterrent market.
Nutriband currently holds patents in 46 countries covering its technology, which incorporates aversive agents into transdermal patches to help prevent abuse, diversion, misuse, and accidental exposure involving drugs with abuse potential, including opioids and stimulants. The company's lead product under development is an abuse-deterrent fentanyl patch that utilizes AVERSA™ technology. For investors, the patent application signals Nutriband's commitment to protecting its proprietary technology and could pave the way for future licensing opportunities or partnerships. More details on the filing can be found in the full press release at https://ibn.fm/Osmxh.
The AVERSA™ technology is designed to be incorporated into any transdermal patch to deter abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. By extending patent protection, Nutriband aims to secure a longer market exclusivity for its products, which is crucial in the pharmaceutical industry where generic competition can erode market share quickly. The company's extensive patent portfolio across 46 countries underscores its global strategy to protect its innovations. For ongoing updates on Nutriband, the company's newsroom is available at https://ibn.fm/NTRB.
MissionIR, a specialized communications platform, distributed the announcement. MissionIR is part of the Dynamic Brand Portfolio at IBN, which offers a range of services including wire distribution through InvestorWire, editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. These services help companies like Nutriband reach a broad audience of investors and stakeholders. For more information, visit MissionIR.
The patent application's potential to extend protection through 2046 could be a game-changer for Nutriband, as it may allow the company to maximize the commercial potential of its abuse-deterrent technology. With the opioid crisis continuing to be a major public health concern, technologies that prevent abuse and misuse are increasingly important. Nutriband's AVERSA™ technology addresses this need, and the patent application demonstrates the company's efforts to safeguard its intellectual property. As the company advances its lead product, AVERSA™ FENTANYL, through development, the strengthened patent protection could enhance its attractiveness to potential partners and investors. The full terms of use and disclaimers for MissionIR content are available at https://www.MissionIR.com/Disclaimer.
